OXARTIS takes ProMatrix BioDerm to SCARS2026 MILAN

SCARS2026, 16-18 January, 2026

OXARTIS, in Collaboration with MENDEDskin raised interest in ProMatrix BioDerm for skin-loss reconstruction

A major theme of the 6th annual conference on scars was reviewing the rapid advances in application of lasers, laser assisted drug delivery, and microdroplet transcutaneous delivery and other focal technologies for treating scars. There were some presentations on the clinical use of dermal scaffolds to reduce the extent of scarring from healing of skin-loss trauma and surgical excision wounds. However, despite reducing the extent of scarring, primary surgical outcomes of skin reconstruction typically result in dysfunctional contractures and disfigurement.

ProMatrix BioDerm scaffold technology offers a radical approach: regenerative reconstruction: prevent the wound healing process from growing scar tissue.

ProMatrix would not obviate the use of treatments for existing scars, but stands to accelerate recovery and rehabilitation from the most severe wounds.

We are very grateful for great interest of the delegates, especially burns and reconstructive surgeons, and we look forward to progressing the essential regulatory evidence needed for clinical use.

Milestone pre-clinical evaluation of ProMatrix BioDerm

Oxartis is glad to announce the completion of a pre-clinical study to evaluate the efficacy of our MVP, ProMatrix BioDerm. The study was conducted in collaboration with Study partner, ProDevLabs, with BridgePTS and Histology Services Ltd.

Methods

Test scaffolds were evaluated for effect on healing or reconstruction of full-thickness excision wounds in Yorkshire pigs. ProMatrix and two predicate products in widespread use globally, were evaluated side by side, together with no-scaffold control wounds, which recieved identical dressing (4 replicate wounds each treatment). All scaffolds were covered with a layer of Telfa semi-permeable plastic membrane, and bolstered with absorbent foam (Optifoam). Wounds were regularly redressed and monitored for 3 weeks by laser speckle for blood flow, sampled for histology. The study was terminated at 6 weeks, with mechanical and TEWL measurements of scar/neotissue outcome, and histology.

Results

Efficacy for dermal regenerative reconstruction (full-thickness skin excision assay, porcine in vivo, 6 weeks).

·       Vascularisation into scaffolds was detected from day 3, and progressively increased to day 14. significantly greater than that achieved by competitor products.

·       Epithelialisation rate (change in area/day) from day 7 to day 21, was 6 - 8 X faster than that achieved by competitor products.

·       TEWL indicating accelerated 2-9 X increased skin barrier restoration at 6 weeks over that achieved by competitor products.

·       Viscoelasticity of reconstructed skin significantly higher at 6 weeks over that achieved by competitor products. Specifically, neo-tissue showed 1.3-1.6 X greater elasticity and 0.6-0.74 X less viscous flow, that each competitor product.

·       Histological analysis revealed that at 6 weeks, the ProMatrix neo-tissue showed dispersed collagen, without formation of dense bundles seen in scar tissue.

Conclusions

The porcine full-thickness excision wound model yielded results which gave statistically significant differences between treatment groups. The healing profile with each predicate is reflective of clinical experience. PMBD treated wounds showed rapid vascularisation into the scaffold, rapid epithelial closure over the wound neo-tissue, and tissue growth. Moreover, tracts of dense and contractile scar tissue collagen were absent from the ProMatrix neo-tissue. Therefore ProMatrix appears to support regenerative tissue reconstruction without scarring.

Oxartis hosts Entrepreneurial Biotechnology Insights visit by eMBA cohort

Oxartis was honoured to participate in an Oxford Prospects eMBA programme on Saturday, by hosting an afternoon in our laboratory for a combination of Lecture and demonstrations. The afternoon was held to be a instructive opportunity for delegates to see the progress of a start-up biotech company.

L-R: Oxartis’s Dr Dye presenting the startup journey tothe eMBA cohort; Dr Nauman Jalil showing our scanning electron microsope in use; Dr Tony Keirouz engaging the delegates in Tissue Scaffold technology.

Oxartis takes on two MSc Reasearch Projects in collboration with UCL

Through our collaboration with UCL Eastman Dental Institute, Oxartis is taking on two MSc Nanotechnology and Regenerative Medicine research projects, focused on characterising particular functional and safety aspects of PMBD material.

Oxartis Team Presents at Advanced Therapies March 2024

The Oxartis team attended and presented their latest development work at Advanced Therapies 2024. This was a fruitful gathering bringing commercial and research organizations together to map future development paths for our pipeline products.

Oxartis wins an IUK RTC award for clean-room manufacturing

8th August 2024

Oxartis has signed an agreement to collaborate with MTIF, Medical Technology Innovation Facility, Nottingham Trent University, to initiate cleanroom manufacture of ProMatrix BioDerm, our first tissue regeneration product, for scarless reconstruction of full-thickness skin loss wounds.

OXARTIS TEAMS UP WITH UCL FOR INNOVATE UK BIOMEDICAL CATALYST PROJECT

Oxartis in partnership with UCL, are launching a landmark product development project supported by an IUK Biomedical Catalyst grant. The grant provides £630,000 of a total project cost of £860,000, to support the pre-clinical development of ProMatrix BioDerm, Oxartis’ lead tissue scaffold product. The collaboration with Dr Linh Nguyen, at the Eastman Dental Institute at University College Hospital, will support the development with some of the nation’s top expertise and technology.

These grants are incredibly competitive, and we are delighted to have been selected as winners. Although it is tough to raise co-funding at an early stage of product development, we are honoured to be able use IUK support to address an urgent un-met clinical need for effective skin reconstruction.

Securing this grant funding has enable Oxartis to establish a laboratory facility at Heyford Park Innovation Centre in the Oxfordshire technology belt, and start work on developing its first clinical product.

OXARTIS WINS BIOKICKSTART COMPETITION

OXARTIS WINS THE OXFORD INNOVATION SPACE BIO KICKSTART COMPETITION 2023

We are delighted to announce that Oxartis was selected as this year’s Bio Kick Start Winner, after a probing pitch and interview contest. Our prize is One year of free laboratory space for a researcher in Heyford Park Innovation Centre, which provides service Laboratory and office space for start up companies.

The prize is sponsored by a number of companies supporting the local startup ecosystem, which is a great help in launching our laboratory operations.

Oxartis joins the Panacea Stars Develop Accelerator

We are honoured and delighted to be selected for the Oxford-based Panacea Stars Accelerator Programme, running through November and December 2022. We have already participated in an entrepreneurs bootcamp, and gained many insights from formal talks and mentoring sessions.

Oxartis selected for the TechTour Health21 Season

Oxartis was selected as one 30 companies from 200 applicants to participate in the TechTour Health 21 Investor pitching and networking events. The Key opening event took place on 27/26th October 2021 within the new Bio-pole Innovation park in Lausanne, and other online events during November.

The TechTour prooved to be a great forum for making introductions to relevant Investors, as well as networking and sharing ideas and experiences with fellow entrepreneurs in Biotech sector.